These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
10. Antibodies in oncology. Pillay V; Gan HK; Scott AM N Biotechnol; 2011 Sep; 28(5):518-29. PubMed ID: 21473941 [TBL] [Abstract][Full Text] [Related]
11. [Tumour angiogenesis inhibition by therapeutic monoclonal antibodies]. Cézé N; Lecomte T; Watier H Med Sci (Paris); 2009 Dec; 25(12):1099-104. PubMed ID: 20035685 [TBL] [Abstract][Full Text] [Related]
12. Small-molecule and antibody approaches to molecular chemotherapy of primary brain tumors. Newton HB Curr Opin Investig Drugs; 2007 Dec; 8(12):1009-21. PubMed ID: 18058572 [TBL] [Abstract][Full Text] [Related]
13. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer. Georganaki M; van Hooren L; Dimberg A Front Immunol; 2018; 9():3081. PubMed ID: 30627131 [TBL] [Abstract][Full Text] [Related]
14. Tumor angiogenesis and accessibility: role of vascular endothelial growth factor. Jain RK Semin Oncol; 2002 Dec; 29(6 Suppl 16):3-9. PubMed ID: 12516032 [TBL] [Abstract][Full Text] [Related]
15. The value and effectiveness of angiogenesis inhibitors for colorectal cancer. Venook AP Clin Adv Hematol Oncol; 2015 Sep; 13(9):561-3. PubMed ID: 26452184 [No Abstract] [Full Text] [Related]
17. Playing only one instrument may be not enough: limitations and future of the antiangiogenic treatment of cancer. Quesada AR; Medina MA; Alba E Bioessays; 2007 Nov; 29(11):1159-68. PubMed ID: 17935210 [TBL] [Abstract][Full Text] [Related]
18. A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Li L; Wartchow CA; Danthi SN; Shen Z; Dechene N; Pease J; Choi HS; Doede T; Chu P; Ning S; Lee DY; Bednarski MD; Knox SJ Int J Radiat Oncol Biol Phys; 2004 Mar; 58(4):1215-27. PubMed ID: 15001266 [TBL] [Abstract][Full Text] [Related]
19. Overview of anti-VEGF therapy and angiogenesis. Part 1: Angiogenesis inhibition in solid tumor malignancies. Ellis LM; Rosen L; Gordon MS Clin Adv Hematol Oncol; 2006 Jan; 4(1):suppl 1-10; quz 11-2. PubMed ID: 16562372 [TBL] [Abstract][Full Text] [Related]
20. Targeting activin receptor-like kinase 1 inhibits angiogenesis and tumorigenesis through a mechanism of action complementary to anti-VEGF therapies. Hu-Lowe DD; Chen E; Zhang L; Watson KD; Mancuso P; Lappin P; Wickman G; Chen JH; Wang J; Jiang X; Amundson K; Simon R; Erbersdobler A; Bergqvist S; Feng Z; Swanson TA; Simmons BH; Lippincott J; Casperson GF; Levin WJ; Stampino CG; Shalinsky DR; Ferrara KW; Fiedler W; Bertolini F Cancer Res; 2011 Feb; 71(4):1362-73. PubMed ID: 21212415 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]